Key result
Periostin is a key factor in osteoporosis and cardiovascular disease, but current evidence is fragmented and does not establish it as a common pivotal biomarker linking these comorbidities.
Why the study?
Osteoporosis and cardiovascular disease often coexist and share risk factors, and identifying common biomarkers could improve preventive care.
Is periostin a common biomarker for osteoporosis and cardiovascular disease?
Is periostin a common biomarker for osteoporosis and cardiovascular disease?
Current evidence is insufficient to establish periostin as a common biomarker linking osteoporosis and cardiovascular disease.
Context: Osteoporosis (OP) and cardiovascular disease (CVD), prevalent disorders worldwide, often coexist and share common risk factors. The identification of common biomarkers could significantly improve patients' preventive care. Objectives: The objectives are 1, to review periostin (Postn) involvement in osteoporosis and in CVD, and 2, identify if Postn could be a common biomarker. Design: This is a scoping review on Postn in OP and CVD. Methods: Databases were searched, in vitro and in vivo, for publications in English on Postn, bone, and the cardiovascular system, with no limit regarding publication date. Results: Postn appears as a key factor in OP and CVD. Its role as a potential biomarker in both pathologies is described in recent studies, but a number of limitations have been identified. Conclusions: Current evidence provides fragmented views on Postn in OP and CVD and does not encapsulate Postn as a common pivotal thread linking these comorbidities. A number of gaps impede highlighting Postn as a common biomarker. There is room for future basic and clinical research with Postn as a marker and a target to provide new therapeutic options for aging patients with concomitant OP and CVD.
No takes yet. Share an insight, caveat, or question.
Pickering et al. (2023) conducted a review in Osteoporosis and Cardiovascular Disease. Periostin was evaluated on Periostin as a common biomarker. Periostin is a key factor in osteoporosis and cardiovascular disease, but current evidence is fragmented and does not establish it as a common pivotal biomarker linking these comorbidities.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: